Raed Al Rajabi, MD
Internal Medicine · Westwood, KSNPI 1992798839
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 27.0% of the total. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $1029.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$13K
- Sirtex Medical Inc$13K
- AstraZeneca$9K
- Taiho Oncology, Inc.$4K
- Incyte Corporation$2K
- Astrazeneca UK Limited$2K
- plus $5K from 9 others
Across 660 payments — averaging $6813.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.4M
- Merck$720K
- Exelixis Inc.$327K
- Incyte Corporation$240K
- Mirati Therapeutics, Inc.$139K
- Bayer$135K
- plus $488K from 11 others
What the payments were for
- Consulting fees$19,68340%
- Speaking & faculty fees$26,62554%
- Travel & lodging$1,0202%
- Food & beverage$1,9944%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 7 | $13,330 |
| Sirtex Medical Inc | 13 | $13,293 |
| AstraZeneca | 6 | $8,827 |
| Taiho Oncology, Inc. | 3 | $4,382 |
| Incyte Corporation | 7 | $2,148 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Exelixis Inc. | 1 | $1,980 |
| Amgen | 1 | $1,500 |
| Bayer | 1 | $760 |
| Eisai Inc. | 1 | $670 |
| Lexicon Pharmaceuticals, Inc. | 2 | $179 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $110 |
| Genentech USA, Inc. | 2 | $57 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$13,213
- ONIVYDE$13,180
- IMFINZI$6,850
- Lonsurf$2,640
- Cabometyx$1,980
- Vectibix$1,500
- Stivarga$760
- LENVIMA$670
- JAKAFI$118
- SOMATULINE DEPOT$117
How this compares
$49,432 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 18 | $394,683 |
| LynparzaOlaparib | 17 | $265,854 |
| CreonLipase/Protease/Amylase | 35 | $103,991 |
| EliquisApixaban | 41 | $35,369 |
| Imatinib Mesylate | 33 | $5,623 |
| Dexamethasone | 63 | $1,082 |
| Olanzapine | 41 | $850 |
| Clobetasol Propionate | 16 | $747 |
| Ondansetron Hcl | 102 | $712 |
| Potassium Chloride | 27 | $662 |
| Duloxetine Hcl | 23 | $573 |
| Gabapentin | 37 | $546 |
| Prochlorperazine Maleate | 57 | $536 |
| Pantoprazole Sodium | 40 | $491 |
| Oxycodone Hcl | 34 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $670 | $394,68318 claims |
| AstraZenecaLynparza | $8,827 | $265,85417 claims |
| Lilly USA, LLCOlanzapine | $110 | $85041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Westwood
- Lauren NyeWestwood$6K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.